HARMON CYRUS (Chief Technology Officer) sold 17.6% of their position (25K shares) of OLEMA PHARMACEUTICALS, INC. on the open market
Open‑market sale worth $204.8K — a significant reduction. Review remaining holdings and any 10b5‑1 plan disclosures.
S · 4 sales
Filed: 9/18/2025ACC: 0001831410-25-000004
DirectorOfficer· Chief Technology Officer
Since Nov 2020
-25K
Net shares
Net seller
$204.8K
Total sold
4
Open market trades
0B · 4S
4
Total transactions
25K disposed
Non-Derivative Transactions4
Common Stock
Direct
Shares
−10K
Price / share
$8.04
Trade value
$80.40K
% of position
1.3%
9/16/2025
764.14K→754.14K
Common Stock
Indirect
Shares
−1.91K
Price / share
$8.08
Trade value
$15.47K
% of position
1.6%
9/16/2025
122.03K→120.11K
Common Stock
Direct
Shares
−10K
Price / share
$8.33
Trade value
$83.30K
% of position
1.3%
9/18/2025
754.14K→744.14K
Common Stock
Indirect
Shares
−3.09K
Price / share
$8.32
Trade value
$25.68K
% of position
2.6%
9/18/2025
120.11K→117.03K
Total
Net shares
−25K
Net value
-$204.84K
| Security | Date | Type | Shares | Price / Share | Trade Value | % of Position | Held Before | Held After |
|---|---|---|---|---|---|---|---|---|
| Common Stock Direct | 9/16/2025 | S · Sale | −10K | $8.04 | $80.40K | 1.3% | 764.14K | 754.14K |
| Common Stock Indirect | 9/16/2025 | S · Sale | −1.91K | $8.08 | $15.47K | 1.6% | 122.03K | 120.11K |
| Common Stock Direct | 9/18/2025 | S · Sale | −10K | $8.33 | $83.30K | 1.3% | 754.14K | 744.14K |
| Common Stock Indirect | 9/18/2025 | S · Sale | −3.09K | $8.32 | $25.68K | 2.6% | 120.11K | 117.03K |
| Total | −25K | -$204.84K | ||||||
Derivative Transactions0
No derivative transactions reported